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Background: Accumulation of T cells and immature dendritic
cells (DCs) is one of the characteristic features of nasal polyps.
However, the question remains why these cells accumulate in
nasal polyp tissue. Macrophage inflammatory protein-3 (MIP-
3/CCL20) is a chemokine involved in the migration of T cells
and immature DCs into inflammatory tissue sites. Fibroblasts are
a rich source of cytokines and chemokines. The objective of this
study was to demonstrate the expression of MIP-3/CCL20 in
nasal polyp fibroblasts after stimulation with proinflammatory
cytokines such as interleukin-17 (IL-17) and tumor necrosis
factor- (TNF-).
Methods: Fibroblast lines were established from nasal polyps.
MIP-3/CCL20 mRNA expression was evaluated by real-time re-
verse transcription-polymerase chain reaction (real-time RT-PCR).
The amount of MIP-3/CCL20 in the supernatants was measured by
enzyme-linked immunosorbent assay (ELISA).
Results: IL-17A and TNF- synergistically induced MIP-3/
CCL20 production by nasal polyp fibroblasts in a dose- and time-
dependent manner. This synergy was observed by stimulation with
TNF- plus IL-17A or IL-17F, but not IL-17E.
Conclusions: Nasal polyp fibroblasts, by producing MIP-3/
CCL20, may play an important role in the recruitment of T cells and
DCs in upper airway inflammatory lesions such as nasal polyps.
Key Words: CCR6 ligand, chronic sinusitis, MIP-3/CCL20,
IL-17 family members
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Chronic sinusitis is characterized by persistent inflam-mation of the sinus, with hyperplasia of the sinus-
lining cells that interact with blood-derived cells.1 Chronic
sinusitis often accompanies nasal polyps. Accordingly, the
sinus mucosae and nasal polyps demonstrate histologic
features that are similar to those in patients with chronic
sinusitis. Many of the features of the chronic sinusitis
environment, such as the presence of T and B cells,
eosinophils, neutrophils and dendritic cells (DCs) in the
sinus mucosa and in nasal polyps, suggest a role for
chemokines. Chemokines could be released by any of
several cell types present in the mucosa, including struc-
tural cells such as epithelial cells and fibroblasts and
hemopoietic cells such as T cells and eosinophils. Recent
advances in sinusitis research have revealed the presence
of the following: IL-8, which attracts neutrophils; MCP-4,
which attracts eosinophils; and RANTES, which recruits T
cells, monocytes, and eosinophils.1,2
The development of chronic sinusitis is known to be
a complex, multifactor process characterized by inflamma-
tion of the sinus mucosa. For example, the sinus mucosa
and nasal polyps are associated with atopy.3,4 It was
reported that, in the case of nonatopic chronic sinusitis,
Th-1 cells are dominant in the ethmoidal mucosa, whereas
TH2 cells are dominant in atopic chronic sinusitis.4 Re-
cently, it was reported that Th17 cells infiltrate nasal
polyps.5 However, the mechanism of this migration by
Th17 cells remains unclear.
Macrophage inflammatory protein-3 (MIP-3)/CCL20
is a CC chemokine identified through bioinformatics, and it is
a unique functional ligand for chemokine receptor-6 (CCR6).
This receptor is selectively expressed on T cells, immature
DCs, and B cells.6–8 Recently, it was shown that CCR6 is a
characteristic of human interleukin-17 (IL-17)–producing T
cells.9 Because MIP-3/CCL20 is expressed in airway dis-
eases,10 it is possible that MIP-3/CCL20 functions as a
chemotactic factor in the migration of Th17 cells and DCs
into the sinus mucosa and nasal polyps in patients with
chronic sinusitis.
To address this issue, we investigated whether cul-
tured nasal polyp fibroblasts produce MIP-3/CCL20 in
response to IL-17A and tumor necrosis factor- (TNF-)
(a proinflammatory cytokine) expressed in the sinus mu-
cosa and nasal polyps in chronic sinusitis patients, and also
examined 2 other IL-17 family members (IL-17E and
IL-17F) for possible effects.
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METHODS
Reagents
Human recombinant IL-17A, IL-17E, IL-17F, IL-4,
and TNF- were purchased from R&D Systems, Inc. (Min-
neapolis).
Cell Source and Culture
Primary fibroblast lines were established from hu-
man polyp biopsy tissues (n  5) removed at polypectomy,
and they were characterized as previously described.11
Only fibroblast lines between the fourth and sixth passages
were used in this study. All the nasal polyp specimens had
been obtained from patients with chronic sinusitis (5
males, aged 45.4  18.6 years (mean  SD)). Two of the
patients were atopic, diagnosed on the basis of elevation of
at least 1 of the capsulated hydrophobic carrier polymer-
radioallergosorbent tests (CAP-RASTs) against 8 common
aeroallergens. Each had a cedar pollen score of 2 or more.
One of them had a house dust CAP-RAST score of 2. One
of the atopic patients had asthma. All subjects had given
written informed consent, and the study protocol was
approved by the Ethics Committee of Nippon Medical
School Hospital.
Before the cytokine assay, fibroblasts (1  104 cells)
were plated in 24-well tissue culture plates (Becton Dickin-
son, Franklin Lakes, NJ). Before real-time polymerase chain
reaction (PCR), fibroblasts (2  106 cells) were plated in
60-mm culture dishes (Corning, NY). Plated fibroblasts were
allowed to grow to confluence in regular growth medium
(Dulbecco’s modified Eagle medium) (Invitrogen, Carlsbad,
CA) containing 10% fetal bovine serum (Invitrogen), peni-
cillin at 100 units/mL, streptomycin at 100 g/mL, and
amphotericin B at 2.5 g/mL. The same culture medium was
used when fibroblasts were exposed to various stimuli. At
specified time points, supernatants were collected and centri-
fuged for cytokine protein assay, and cells were collected for
RNA extraction.
Analysis of MIP-3/CCL20 mRNA by
Quantitative Real-Time Reverse
Transcription-Polymerase Chain Reaction
Total cellular RNA was extracted and purified using an
RNeasy Mini Kit (Qiagen, Valencia, CA). The total RNA, 2
g, was reverse-transcribed at 37°C for 60 minutes using
random primers (Takara Biochemicals, Tokyo) and Omnis-
cript reverse transcription (Qiagen) according to the manu-
facturers’ protocols.
Quantitative real-time RT-PCR was carried out using
the TaqMan assay and ABI Prism 7700 Sequence Detection
System (Applied Biosystems, Foster City, CA). The primers
and fluorogenic probes for MIP-3/CCL20 and -actin were
purchased from Applied Biosystems. The amplification con-
ditions were 2 minutes at 50°C, 10 minutes at 95°C, and 40
cycles of 15 seconds at 95°C and 60 seconds at 60°C.
Data analysis was performed using sequence detector
system software (Applied Biosystems). Threshold cycles
were used to calculate arbitrary mRNA concentrations by the
relative standard curve method. The standard curve was
constructed using serial dilutions of cDNA containing the
message for MIP-3/CCL20. The level of MIP-3/CCL20
mRNA was normalized against the level of -actin mRNA.
Cytokine Assay
The levels of MIP-3/CCL20 in culture supernatants
were measured by an enzyme-linked immunosorbent assay
(ELISA) using a commercially available human MIP-3/
CCL20 ELISA kit (R&D Systems). The sensitivity of this
assay system was more than 7.8 pg/mL. The data are pre-
sented as nanograms of MIP-3/CCL20 per 1  106 cells.
Statistical Analysis
The paired Wilcoxon test was used for statistical anal-
ysis. A P value of 0.05 was considered statistically signif-
icant.
RESULTS
Effect of IL-17 and TNF- on MIP-3/CCL20
Production by Nasal Polyp Fibroblasts
Nasal polyp fibroblasts were cultured alone or with
IL-17A (10 ng/mL) and TNF- (10 ng/mL), alone and in
combination. Negligible MIP-3/CCL20 [0.11  0.02
(ng  mL1)/106 cells; mean  SEM] was produced in the
absence of IL-17A and TNF-. Production of MIP-3/
CCL20 [0.65  0.19 (ng  mL1)/106 cells] was weak in the
presence of IL-17A, whereas TNF- induced moderate MIP-
3/CCL20 production [2.80  0.23 (ng  mL1)/106 cells;
Fig. 1]. The combination of IL-17A and TNF- showed
synergistic induction of MIP-3/CCL20 production by the
nasal polyp fibroblasts [13.14  0.94 (ng  mL1)/106 cells;
Fig. 1]. The release of MIP-3/CCL20 by the nasal polyp
fibroblasts occurred in a dose- and time-dependent manner. In
time-course experiments, the MIP-3/CCL20 concentration
increased steadily over time, and the synergy between IL-
17A and TNF- was observed throughout the experiment
(Fig. 2). The above-described synergy between IL-17A and
TNF- was demonstrated using 10 ng/mL of IL-17A and
10 ng/mL of TNF-. We then tested a series of various
combinations of concentrations of IL-17A and TNF-. The
synergy between IL-17A and TNF- became more prom-
inent with each increase in the concentration of both
IL-17A and TNF- (Fig. 3).
Real-time PCR was performed for quantitation of the
MIP-3/CCL20 mRNA levels. The expression of MIP-3/
CCL20 mRNA was weak or undetectable in the unstimulated
cells. Upon incubation with IL-17A or TNF-, MIP-3/
CCL20 mRNA expression was upregulated after 10 hours of
stimulation. Combined stimulation with IL-17A and TNF-
induced further upregulation of MIP-3/CCL20 expression in
the nasal polyp fibroblasts (Fig. 4).
Comparison of Synergistic Effects of IL-17
Family Members (A, E, and F) and TNF- on
Nasal Polyp Fibroblasts
We next examined the synergistic effects of several
IL-17 family members and TNF- on nasal polyp fibro-
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blasts. Combined stimulation with TNF- plus IL-17A or
IL-17F, but not IL-17E, synergistically induced release of
MIP-3/CCL20 by the nasal polyp fibroblasts. Figure 5
shows that 72-hour stimulation with IL-17A and TNF-
induced about 5 times as much MIP-3/CCL20 [13.14 
0.94 (ng  mL1)/106 cells; mean  SEM] as that released
by TNF- alone [2.80  0.23 (ng  mL1)/106 cells], and
costimulation with IL-17F and TNF- induced about 2 to
3 times as much MIP-3/CCL20 [7.59  0.83
(ng  mL1)/106 cells] as that released by TNF- alone.
The increase in the release of MIP-3/CCL20 was statis-
FIGURE 1. Effects of IL-17A and TNF- on MIP-3/CCL20
release by nasal polyp fibroblasts. Cells were cultured with
IL-17A (10 ng/mL) and TNF- (10 ng/mL), alone and in
combination, and also without stimulation with either, for
72 hours. The MIP-3/CCL20 concentration in the culture
supernatant was measured by ELISA. Box plots show the me-
dian values for the 25% and 75% interquartiles; the error
bars represent the 10th and 90th percentiles (n  5). *, P 
0.05 compared with unstimulated cells. Abbreviation: C,
control.
FIGURE 2. Kinetics of MIP-3/CCL20 accumulation in su-
pernatants of nasal polyp fibroblast cultures. Cells were stim-
ulated with IL-17A (10 ng/mL) (F), TNF- (10 ng/mL) (f),
or IL-17A and TNF- (Œ). Supernatants were assayed for
MIP-3/CCL20 after 24, 48, 72, and 96 hours of culture.
Results shown are from the average of 2 experiments.
FIGURE 3. Dose-effect curves for IL-17A and TNF- on
MIP-3/CCL20 production by nasal polyp fibroblasts. Cells
were stimulated with a series of concentrations of IL-17A
and a series of TNF- concentrations (f, 0 ng/mL; F, 0.1
ng/mL; Œ, 1.0 ng/mL; , 10 ng/mL) for 72 hours. Results
shown are from the average of 2 experiments.
FIGURE 4. Effects of IL-17A and TNF- on MIP-3/CCL20
mRNA expression by nasal polyp fibroblasts. Cells were stim-
ulated with IL-17A (10 ng/mL) and TNF- (10 ng/mL), alone
and in combination, for 10 hours, and real-time PCR was
performed. Box plots show the median values for the 25%
and 75% interquartiles from 3 donors, each studied in tripli-
cate; the error bars represent the 10th and 90th percentiles.
The results are normalized against -actin expression. **, P 
0.01 compared with unstimulated cells. Abbreviation: C,
control.
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tically significant only with IL-17A (Fig. 1) (data for
IL-17E and IL-17F are not shown).
DISCUSSION
It is known that when naive CD4 T cells recognize an
antigen and are activated, they differentiate into 2 subsets
having distinct properties of TH1 and TH2 and they are both
heterogeneous populations of effector/memory cells.12 Het-
erogeneity is a particularly prominent feature of the effector/
memory CD4 T-cell population, which induces subsets
capable of producing polarized patterns of cytokines that
serve specialized functions and have profound effects on
the quality of the immune response.13 It has recently been
learned that, in a new helper T-cell population having
characteristics different from TH1 and TH2, IL-23, which is
structurally and functionally similar to IL-12, is deeply
involved in promotion of differentiation into Th-17 cells
that specifically produce IL-17 without producing IFN-,
IL-4, or IL-13 and also in induction of inflammation and
some immunity to infections.14
Recent studies have suggested that human heteroge-
neous populations of effector/memory cells display distinct
patterns of chemokine receptor expression, which are respon-
sible for the differences in patterns of migration by effector/
memory versus naive cells.15 CXCR3 and CCR5 are ex-
pressed preferentially on human TH1 cells. Conversely,
CCR4 is expressed preferentially on TH2 cells. It is likely that
these receptors are components of positive-feedback loops to
reinforce type 1 or type 2 responses in tissues because
CXCR3 ligands are induced by interferon-, the signature
cytokine of TH1 cells, and CCR4 ligands are induced by IL-4,
the signature cytokine of TH2 cells. Recently, it was reported
that CCR6 is a characteristic of human IL-17–producing T
cells.9 CCR6 is expressed on dendritic cells, B cells, and
Th17 cells, and it has only 1 chemokine ligand, MIP-3/
CCL20, whose only receptor is CCR6. CCR6 has been
reported to have roles in host defense and inflammation.16,17
In humans, CCR6 and/or MIP-3/CCL20 have been impli-
cated in the pathogenesis of rheumatoid arthritis and inflam-
matory bowel disease, autoimmune disorders in which Th17
cells are thought to play a crucial role.18,19 It was also
reported that CCR6 and/or MIP-3/CCL20 contributed to
airway inflammatory diseases. In mouse models of immune
response and diseases, CCR6 and/or MIP-3/CCL20 were
required in allergic pulmonary inflammation20 and contrib-
uted to ozone-induced airway hyperresponsiveness21 and the
pathogenesis of cigarette smoke–induced pulmonary inflam-
mation.22 MIP-3/CCL20 levels in bronchoalveolar lavage
from patients with allergic airway inflammation significantly
increased and correlated with the allergen-driven influx of
lymphocytes after segmental allergen challenge.23 Consider-
ing our data, MIP-3/CCL20 may play a role in upper airway
diseases such as chronic sinusitis by recruiting Th17 cells and
DCs into nasal polyps.
Chronic sinusitis is defined as sinus inflammation per-
sisting for more than 8 to 12 weeks. It is known that the
development of chronic sinusitis is a complex multifactor
process characterized by inflammation of the nasal and sinus
mucosae. Many studies have shown that the inflammatory
cells in chronic sinusitis consist of T and B lymphocytes,
DCs, and eosinophils.24 Nasal polyps are benign outgrowths
of the mucosa in the nasal and paranasal cavities, and they
can accompany chronic sinusitis. When nasal polyps accom-
panying chronic sinusitis were classified on the basis of being
atopic or nonatopic (determined by allergy skin testing) and
their cytokine profiles were analyzed, it was found that IFN-
expression was increased in the nonatopic nasal polyps,
whereas IL-4 and IL-5 expressions were increased in the
atopic nasal polyps.3 However, increased TNF- expression
was observed in both atopic and nonatopic nasal polyps.3
Elhini et al4 similarly classified the ethmoidal mucosa in
chronic sinusitis into nonatopic and atopic types (determined
by the RAST and the total serum IgE level), and the predom-
inant helper T-cell subsets were investigated. The results
showed that the nonatopic ethmoidal mucosa had more cells
expressing CCR5 (TH1 cells), whereas the atopic ethmoidal
mucosa had more cells expressing CCR4 (TH2 cells). Fur-
thermore, the number of CCR4 cells showed a positive
correlation with the total serum IgE level, whereas the num-
ber of CCR5 cells showed a negative correlation with the
total serum IgE level.4 It was recently reported that expres-
sion of IL-17 is increased in nasal polyps.5 In addition, that
same study found that the IL-17–producing cells in the nasal
polyps consisted of 43.3% T lymphocytes.5 Accordingly,
even in chronic sinusitis, it can be surmised that there are 3
different types of inflammation, that is, TH1 type, TH2 type,
and Th17-type. The mechanisms underlying the infiltrations
FIGURE 5. Effects of IL-17 family members (A, E, and F)
and TNF- on MIP-3/CCL20 release by nasal polyp fibro-
blasts. Cells were stimulated with IL-17 family members (A
or E or F) and TNF-, alone and in combination, for 72
hours. Box plots show the median values with 25% and
75% interquartiles; the error bars represent the 10th and
90th percentiles (n  5).
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by TH1 cells and TH2 cells have been investigated for many
years, but to date study of the mechanism underlying Th17
cell infiltration has been inadequate.
However, in the present study, we have demonstrated
that IL-17A and TNF- synergistically induced MIP-3/
CCL20 in nasal polyp fibroblasts. This induction occurred in
a dose- and time-dependent manner. Although epithelial cells
are thought to be the primary source of MIP-3/CCL20,25
this study showed that nasal polyp fibroblasts are another
source of this chemokine. When IL-23 is expressed at mu-
cosal sites, it has the ability to differentiate Th cells into Th17
cells.14 It is interesting to speculate whether IL-17A, which is
released from Th17 cells, is capable of inducing MIP-3/
CCL20 production in nasal polyp fibroblasts synergistically
with TNF-, which is abundant in nasal polyps. MIP-3/
CCL20, which is released locally, may in turn induce Th17
cells and DCs to migrate out of the vasculature into sites of
inflammation via CCR6. This MIP-3/CCL20/CCR6 posi-
tive-feedback loop involving Th17 cells, DCs, and fibroblasts
amplifies the IL-17 inflammatory response in nasal polyps.
The MIP-3/CCL20/CCR6 loop would be analogous to loops
involving CXCR3 and its ligands and CCR4 and its ligands
for type 1 and type 2 inflammation, respectively.
IL-17A was cloned first, and 6 other IL-17 family
members (IL-17A, -17B, -17C, -17D, -17E, and -17F) have
subsequently been described. Recently, Ishigame et al26 re-
ported differential roles for IL-17A and IL-17F in host
immune and defense mechanisms. In host defense against
mucoepithelial infection, IL-17A was produced mainly by T
cells, whereas IL-17F was produced by T cells, innate im-
mune cells, and epithelial cells. Both cytokines activated
epithelial innate immune responses, and IL-17A, but not
IL-17F, efficiently induced cytokines in macrophages.26
Among the IL-17 family members, the IL-17F isoforms 1 and
2 (ML-1) have the highest degree of homology with IL-17A
(55% and 40%, respectively), followed by IL-17B (29%),
IL-17D (25%), IL-17C (23%), and finally IL-17E, the most
distant (17%).27 Because IL-17F has a high degree of homol-
ogy with IL-17A and has a similar spectrum of activity in
terms of induction of G-CSF and CXCL8, perhaps IL-17F
also uses IL-17R, a receptor for IL-17A, for signaling. Con-
sidering that IL-17E uses IL-17RB, one of the other receptors
for IL-17 family members, IL-17R may be necessary for the
synergistic induction of MIP-3/CCL20 by IL-17A and
TNF- and by IL-17F and TNF-. Further investigations are
needed to clarify the mechanism(s). Increasing evidence
shows that IL-17 family members play active roles in inflam-
matory diseases, autoimmune diseases, and cancer. Among
the IL-17 family members, expression of IL-17A, -17E, and
-17F has been documented in lower airway diseases.10,28,29
Our results suggest that IL-17A and IL-17F, but not IL-17E,
contribute to infiltration of Th17 cells and DCs into upper
airway inflammatory sites such as nasal polyps through the
production of MIP-3/CCL20 by fibroblasts.
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